Latest news
StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTMapLight CEO on what investors missed in the biotech’s schizophrenia data - BioPharma DiveBioPharma Dive · Wed, 29 Jul 2026 07:00:00 GMTMapLight Therapeutics stock crashes on Phase II schizophrenia data - Clinical Trials ArenaClinical Trials Arena · Tue, 28 Jul 2026 14:17:49 GMTMorgan Stanley Reaffirms "Equal Weight" Rating for Maplight Therapeutics (NASDAQ:MPLT) - MarketBeatMarketBeat · Tue, 28 Jul 2026 12:40:02 GMTMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila TimesThe Manila Times · Mon, 27 Jul 2026 11:17:27 GMTMapLight shares sink on mixed ph. 2 schizophrenia readout - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMTMapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMTMaplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMT